On September 24, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lead Author: Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center
Session Title: Pancreatic cancer
Poster Number: 3189TiP
Date and Time: Sunday, October 25, 2026, 12:00-12:45 pm CET

Full abstracts will be published on the ESMO (Free ESMO Whitepaper) website on October 19, 2026, at 00:05 CEST. Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, SEP 24, 2026, View Source [SID1234671051])